A Prospective, Double-Blind, Placebo-controlled Study of Suramin in Subjects With Furosemide-Resistant Acute Kidney Injury (AKI): Efficacy in Preventing Dialysis Dependent AKI
Latest Information Update: 08 May 2023
At a glance
- Drugs Suramin sodium (Primary)
- Indications Acute kidney injury
- Focus Therapeutic Use
- Sponsors Rediscovery Life Sciences
- 01 May 2023 Planned End Date changed from 31 May 2023 to 22 Dec 2023.
- 01 May 2023 Status changed from recruiting to active, no longer recruiting.
- 16 Dec 2021 Planned End Date changed from 1 Aug 2022 to 31 May 2023.